T.TO 0.13ENB.TO 0.8BEP.UN.TO -1.15CP.TO 1.15VRT -19.67NVDA -7.33TSM -15.23JPM -6.1
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

27.72
-0.00 (0.00%)
as of Sep 14, 2026, 8:00:00 pm Market Open.
583 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconSep 14, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Pfizer Inc. (PFE) is perceived as a defensive stock with an attractive dividend yield around 6-7%, appealing to income-focused investors. However, many experts express concern about the company's growth potential following a reliance on COVID-19 vaccine revenues, which have receded. The consensus indicates that while PFE maintains a low valuation (PE around 8-10x), its growth is stagnant or uncertain due to impending patent expirations and the challenges associated with developing new blockbuster drugs. Moreover, there are worries that the ongoing focus on acquisitions may not lead to the anticipated revenue boosts. Despite these concerns, some analysts suggest PFE could still perform well for patient investors, especially as sector interest begins to build. Ultimately, the outlook remains cautious, with a preference noted for other stocks in the pharmaceutical sector that exhibit better growth trajectories.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
LLY
DON'T BUY

Pfizer Inc(PFE)

Nov 10, 2010
Lost its ability to grow because of its size. Lipitor represents 20% and it goes off patent next year so they’ll be competing with generics.
Photo of Gordon ReidGordon ReidUnlock Rating
$16.83

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Nov 09, 2010
(Top Pick Nov 16/09, Down 5%) Drug stocks have been out of favour. Drug stocks bottomed earlier this year. Have a number of drugs coming off patent. Dividend investors have identified drug companies as targets.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$16.83

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Nov 08, 2010
(Top Pick Nov 30/09, Down 4.77%) $28.23 model price. 64% upside. He keeps on buying it. Held for 4 years in his fund. There is value there and major consolidation going on there. It’s a changing landscape – they are getting together with generics.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$17.05

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Oct 20, 2010
The whole pharma business is somewhat challenged. They spend lots developing a drug and then a few years later it goes Generic. One drug is a quarter of their business but it goes Generic in 2011. There are better places to go. This is more of a defensive stock. Would prefer a hybrid that just has pharma as a part of the their business.
Photo of Gordon ReidGordon ReidUnlock Rating
$17.66

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Oct 05, 2010
(A Top Pick Oct 8/09. Up 5.36%.) Still likes.
Photo of Colin StewartColin Stewart
Owned
Unlock Rating
$17.23

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Sep 07, 2010
Has been a long-term sufferer. Product outlook is much better since the merger. They have started to increase their dividend again. This is a dividend stock with some upside potential.
Photo of Norman LevineNorman Levine
No
Unlock Rating
$16.33

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

May 25, 2010
(Market Call Minute) Doesn’t buy US stocks.
Photo of Barry SchwartzBarry SchwartzUnlock Rating
$15.06

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 21, 2010
Pharma model, i.e. spending a boatload of money developing drugs and getting it into market, is really stumbling. Then the clock starts ticking with generics coming in down the road. Lipitor expires next year.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$16.60

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
DON'T BUY

Pfizer Inc(PFE)

Apr 14, 2010
Their big drug Lipitor comes off patent next year, which will be a lot of revenue that will be difficult to replace. Have an “OK” pipeline. Because of their size, it takes a huge blockbuster drug to turn the needle to a positive direction.
Photo of Don LatoDon LatoUnlock Rating
$17.07

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Apr 12, 2010
$2 in annualized earnings. Very cheap stock. Doesn't have the growth that it used to. Have global growth and is a beneficiary of the decline in the US$.
Photo of John ZechnerJohn Zechner
Owned
Unlock Rating
$17.29

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Apr 08, 2010
Like it for its dividend of about 4.1%. Very high cash flow. Have diversified their product line with the acquisition of Wyeth.
Photo of Stan WongStan Wong
Owned
Unlock Rating
$17.14

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Pfizer Inc(PFE)

Apr 05, 2010
(Market Call Minute) If it came down a little bit be would be much more interested.
Photo of Benj GallanderBenj GallanderUnlock Rating
$16.90

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 25, 2010
Great company with a great yield and trading at a very low multiple. Pharmaceutical industry made so much money on their blockbuster drugs but that dried up. This company has made some good acquisitions and are continuing to cut costs. Pipeline is reasonable but you're not going to see the big blockbuster drugs in the next several years.
Photo of Paul Harris, CFAPaul Harris, CFAUnlock Rating
$17.39

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 24, 2010
Wouldn't own any US pharmaceutical companies. Research pipeline cupboard is really bare. Doesn't see any growth. A lot of generic competition.
Photo of Barry SchwartzBarry Schwartz
No
Unlock Rating
$17.61

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 23, 2010
Pfizer (PFE-N) and Merck (MRK-N) are pretty fully priced at current levels. Growth prospects are not that great, especially with a lot of drugs coming off patent. Multiple looks attractive and dividend looks okay but there are better places to go in pharmaceuticals. Prefers Abbott Labs (ABT-N).
Photo of Don LatoDon Lato
No
Unlock Rating
$17.54

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
Showing 451 to 465 of 890 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

TPZ.TO 0.13$12.73
KBL.TO 0.98$42.9
PPL.TO -0.14$66.12
AQN.TO 0.11$7.46
EMA.TO -0.02$68.17

Today's Top Picks

T.TO 0.13$12.73
ENB.TO 0.8$67.03
BEP.UN.T… -1.15$40.98
CP.TO 1.15$124.99
VRT -19.67$237.39

Popular Articles

Latest Sell Signals

CPX.TO 1.15$124.99
AVGO -17.27$344.72
APP 10.28$334.24
XRE.TO 0.05$15.73
ORCL -5.49$144.79

Most Recent Experts

Ryan Bushell

Ryan Bushell

Newhaven Asset Management

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like